Introduction
In man the biosynthesis of both urea and arginine requires four enzymes in common; carbamyl phosphate synthetase (EC 2.7.2.2) (CPS),' ornithine transcarbamylase (EC 2.1.3.3) (OTC), argininosuccinic acid synthetase (EC 6.3.4.5) (AS) and argininosuccinase (EC 4.3.2.1) (AL). Arginine should thus be an essential amino acid for infants with inborn errors of ureagenesis (apart from arginase deficiency) unless there is an unknown pathway for arginine biosynthesis. However, data supporting Receivedfor publication 10 January 1984 and in revisedform 30 July 1984.
1. Abbreviations used in this paper: AL, argininosuccinase; AS, argininosuccinic acid synthetase; CPS, carbamyl phosphate synthetase; OTC, ornithine transcarbamylase.
this prediction have not been reported. Furthermore, the time course of the effect of arginine deprivation on waste nitrogen metabolism is unknown. This study is designed to evaluate the role of arginine in such patients by substituting ornithine for arginine in approximately equimolar proportions to maintain an isonitrogenous intake (assuming that two of the nitrogen atoms of arginine are destined for urea synthesis and excretion). Provision of ornithine also assures that residual ureagenesis (if any) will not be limited by lack of ornithine. Previous studies of arginine deprivation in children showed no change in nitrogen balance (1) . Management Results Fig. 1 shows the results in a 3-mo-old infant with CPS deficiency. Within 24 h after the arginine supplement was discontinued his plasma ammonium and glutamine levels (micromolar) increased from 30 (normal limits <35) and 675 (normal limits 483±86) to 180 and 1,812, respectively. The hyperammonemia that was accompanied by lethargy and vomiting promptly responded to intravenous arginine HCl and sodium benzoate. Plasma levels of arginine and ornithine (normal limits 85±26 and 43.8±11 respectively) changed little. Urinary urea nitrogen excretion fell from 1.6 mg to 0.6 mg nitrogen/mg creatinine (normal range for fasting infants is 10-30 mg [8] ). Not shown in Fig. 1 are urinary orotate levels that remained normal (<0.01 mg/mg creatinine) and plasma levels of alanine, proline, and glutamate that also were unchanged. Fig. 2 shows the results in a 1-mo-old patient with OTC deficiency. Within 15 h after arginine was discontinued the plasma ammonium and glutamine levels (micromolar) increased from 8 was demonstrated. Urinary orotate excretion increased dramatically to 0.67 mg/mg creatinine 30 h after arginine was withdrawn. The addition of citrulline resulted in a prompt return of the plasma ammonium, arginine, and glutamine levels toward normal as well as a decrease in urinary orotate. Not shown in Fig. 2 are alanine levels that increased from 280 to 488 ,uM after arginine withdrawal and decreased to 237 when citrulline was added. Proline and glutamate levels were unchanged. period while urinary urea excretion fell to nearly zero. Restoration of arginine to the diet at a dose of 1.7 mmol* kg-' d-' (with ornithine acetate maintained 1.7 mmol* kg-' d') resulted in a prompt decrease in the plasma glutamine level and an increase in the plasma arginine level and urinary urea nitrogen excretion. Not shown in Fig. 3 are alanine levels, which increased from 167 to 449 after arginine withdrawal and decreased to 264 when arginine therapy was resumed. Glutamate levels also increased (44-130), whereas proline levels were unchanged. Also not shown in Fig. 3 is the urinary orotate excretion, which remained normal throughout the study. Fig. 4 shows the effect of interruption of arginine intake in a 2-yr-old patient with AL deficiency. Within 22 h the plasma ammonium and glutamine levels increased from 38 and 589 to 182 and 887 uM, respectively, while the arginine level decreased from 117 to 28 uM. During the hyperammonemic period he was lethargic and irritable. Urinary urea nitrogen decreased from 2.2 to 0.68 mg/mg creatinine. Urinary orotate excretion remained below 0.01 mg/mg creatinine until 48 h after arginine was discontinued, at which time it increased to 0.048. The hyperammonemia increased to 192 despite an intravenous dose of sodium benzoate (250 mg. kg-' over 1 h) but promptly responded to intravenous arginine HCl (4 mmol/ kg over 1 h followed by 3 mmol -kg-' d-'). Not shown in Fig.  4 are plasma alanine levels that increased slightly from 242 to 390 MM after arginine withdrawal and decreased to 267 uM after arginine was restored. Plasma glutamate levels increased slightly but proline levels were unchanged during the study.
Discussion
Nitrogen accumulation. Withdrawal of supplemental dietary arginine led to nitrogen accumulation as ammonium or glu- tamine or both in all four patients tested. Plasma ammonium levels increased in three patients (Figs. 1, 2 , and 4), all of whom were symptomatic with one or more clinical manifestation of hyperammonemia; vomiting, lethargy, or irritability. The hyperammonemia promptly responded to repletion of arginine. That arginine synthesis from citrulline is unimpaired in OTC deficiency is shown in Fig. 2 where citrulline administration resulted in a decrease in the plasma ammonium and glutamine levels and an increase in arginine levels as promptly as did arginine administration in the CPS deficient patient (Fig. 1 ). Citrulline as a substitute for arginine would not be effective in those diseases where the pathway for citrulline to arginine was interrupted; i.e., deficiencies of AS and AL. The largest amount of nitrogen accumulation in response to the withdrawal of arginine resided in glutamine, the plasma level of which increased by 250-500%. If similar percentage increases occurred in intracellular glutamine levels (which normally are '-30-fold greater (9) than plasma levels) the amount of nitrogen accumulated could be as high as 256 mg.
kg-' (assuming the plasma level increased by 750 uM as in Fig. 2 and intracellular and extracellular water to be 40 and 20% of the body weight, respectively). In all cases the glutamine level promptly returned toward normal when arginine or citrulline was restored to the diet.
Nitrogen also accumulated as alanine and glutamate, but these changes were relatively small as compared with glutamine.
Indirect evidence of nitrogen accumulation as carbamyl phosphate in the OTC deficient (Fig. 2) and AL deficient (Fig.  4) patient may be adduced from the marked increase and subsequent decrease of orotic aciduria as arginine was withdrawn and subsequently restored. Orotic aciduria is ordinarily a constant finding in hyperammonemic OTC deficient patients but has only rarely been described in patients with AL deficiency (10) . The lack of an orotic aciduric response of the AS-deficient patient is compatible with the absence of hyperammonemia, which is presumably a consequence of the small arginine supplement she received.
Plasma arginine, urea, and ornithine levels. In three of the four patients plasma arginine levels decreased immediately after its withdrawal and increased after its restoration. The mechanism that maintained the plasma arginine in the CPSdeficient patient is unclear although it is possible that arginine residues derived from proteolysis were produced at a rate similar to arginine degradation.
That exogenous arginine plays a major role in sustaining the plasma urea concentration in patients with inborn errors of ureagenesis is shown in Figs. 1-4 (12) . To the extent that there is residual activity of a defective urea cycle enzyme in these patients, a reduction in carbamyl phosphate synthetase activity consequent to N-acetylglutamate underproduction would have an adverse effect on whatever low urea synthetic capacity may be present. However, it is unlikely that arginine deficiency in these cases exerted such an effect because two patients demonstrated an increase in urinary orotate; evidence suggesting that substantial synthesis of carbamyl phosphate did take place.
Notwithstanding the above explanations, the hyperammonemia, hyperglutaminemia, and orotic aciduria that occurred in the AL-deficient patient remain puzzling because maintenance of ornithine supply should have supported waste nitrogen excretion as argininosuccinate to the same extent as did arginine. The maintenance of plasma ornithine levels by ornithine substitution would seem to rule out the possibility that intramitochondrial ornithine deprivation could account for reduced argininosuccinate or residual urea synthesis. Although intramitochondrial ornithine degradation via ornithine aminotransferase occurs in extrahepatic tissues, (13) there is little reason to expect organ-specific extracellular-mitochondrial ornithine transport that would preferentially divert ornithine from the liver.
Unexamined in this report is the role of arginine as an amidino donor in the biosynthesis of guanidoacetate, creatine or other such compounds.
Perhaps the most important clinically relevant finding described here is the rapidity with which infants with inborn errors of urea synthesis develop symptomatic hyperammonemia. Such infants clearly require medical attention whenever the intake of arginine or other medications are interrupted or whenever the early signs of hyperammonemia (vomiting, irritability or lethargy) occur.
These results show that arginine is an essential amino acid in children with inborn errors of urea synthesis; therefore, dietary arginine (or citrulline in patients with deficiencies of CPS or OTC) supplementation is necessary.
